- Previous Close
0.0450 - Open
0.0450 - Bid 0.0400 x --
- Ask 0.0500 x --
- Day's Range
0.0450 - 0.0500 - 52 Week Range
0.0400 - 0.1000 - Volume
48,000 - Avg. Volume
46,947 - Market Cap (intraday)
14.032M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date Mar 28, 2025 - Apr 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
www.resverlogix.comRecent News: RVX.TO
View MorePerformance Overview: RVX.TO
Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVX.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVX.TO
View MoreValuation Measures
Market Cap
14.03M
Enterprise Value
26.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.37%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.23M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
43k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
901.12k